ST. GALLEN, Switzerland, Jan. 11 /CNW/ - This bi-annual conference will
highlight meaningful advances concerning treatment of Early Breast
Cancer (EBC). The conference will build up on earlier diagnostic and
therapeutic recommendations and thereafter provide written guidelines
for the international community. Breast cancer specialists from all
over the world are awaiting these new guidelines.
Until recently, patients with HER2 positive breast cancer had to face
inferior prognosis. Now, a part of these patients may be cured from
New therapeutics (PARP inhibitors) will be used in the clinical setting,
especially in patients with tripple-negative breast cancer.
Bisphosphonates are used in treatment of bone metastases, but they are
increasingly expected to prevent disease relaps.
Advancements in molecular cancer diagnostics allow individual, targeted
treatment. This means less treatment burden. Fewer women need
chemotherapy - but rather antihormonal treatment.
Concluding highlights: Medical progress and increasingly complex and
individual diagnostic and therapeutic strategies require cancer care in
certified breast centers, says Prof. Dr. med. Hans-Jorg Senn,
Chairperson of the St. Gallen Breast Cancer Conference and partner at
the tumor- and breast center ZeTuP in St. Gallen.
The international conference with 4500-5000 specialists from all over
the world is organized by the Foundation St. Gallen Oncology
Conferences (SONK). This unique event is one of the most important
worldwide for two reasons:
Recommendations for diagnoses and treatment of EBC are developed by an
open consensus-process: a panel of over 40 international breast cancer
experts discusses topical issues. This process takes place in front of
thousands of conference participants during several hours. The
consensus panel is then editing the internationally accepted
guidelines, which are published two months later.
The Consensus Conference and its recommendations are based on scientific
evidence and on patient-orientated care and are independent from
politics and pharmaceutical industry.
Important: To speed up free access for media representatives,
pre-registration is required (online-registration and further
Sender: Prof. Dr. med. Hans-Jorg Senn, Chairperson, St. Gallen,
SOURCE St.Gallen Oncology Conferences (SONK)
For further information:
Information: Dr.med. Thomas Ferber, media representative in charge, firstname.lastname@example.org
Conference Manager: Judith Eberhardt: email@example.com, +41-71-243-02-81